Anti-PD-1 monoclonal antibody Clinical Trials
16 recruitingDrug
Phase 211Phase 18Not Applicable2
Showing 1–16 of 16 trials
Recruiting
Phase 2
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University31 enrolled1 locationNCT05182957
Recruiting
Phase 1Phase 2
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Solid TumorMelanoma Stage IV
Georgiamune Inc117 enrolled11 locationsNCT06425926
Recruiting
Phase 1
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
Prostate Cancer PatientsRecurrent Prostate CancerOligometastatic Prostate Cancer (OMPC)+1 more
University of Wisconsin, Madison14 enrolled1 locationNCT07090148
Recruiting
Phase 1Phase 2
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
Pancreatic CancerAdvanced CancerPancreatic Ductal Adenocarcinoma+1 more
Changhai Hospital30 enrolled1 locationNCT04146298
Recruiting
Phase 1Phase 2
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Advanced Solid Tumors
LigaChem Biosciences, Inc.300 enrolled8 locationsNCT05941507
Recruiting
Phase 2
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Renal Cell CarcinomaRadiotherapyImmune Checkpoint Inhibitor
Jinling Hospital, China35 enrolled1 locationNCT06255223
Recruiting
Phase 1Phase 2
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
Relapsed/Refractory Primary Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University38 enrolled1 locationNCT06556199
Recruiting
Phase 1Phase 2
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Solid Tumor
Corbus Pharmaceuticals Inc.156 enrolled26 locationsNCT06603844
Recruiting
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD300 enrolled2 locationsNCT05713994
Recruiting
Not Applicable
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Hepatocellular CarcinomaBiliary Tract CarcinomaColorectal Adenocarcinoma+1 more
Zhejiang Cancer Hospital120 enrolled1 locationNCT06349044
Recruiting
Not Applicable
Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer
NSCLC
Energenx Medical LTD.10 enrolled1 locationNCT05987345
Recruiting
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Tongji Hospital300 enrolled4 locationsNCT05717738
Recruiting
Phase 2
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences173 enrolled1 locationNCT06170710
Recruiting
Phase 2
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
Gastroesophageal-junction CancerGastroesophageal Junction AdenocarcinomaMetastatic Cancer+6 more
Fudan University55 enrolled1 locationNCT06121700
Recruiting
Phase 1Phase 2
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors
Chinese PLA General Hospital40 enrolled1 locationNCT05699811
Recruiting
Phase 1Phase 2
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
High-Risk Localized Soft Tissue Sarcoma
Fudan University52 enrolled1 locationNCT05774275